Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Analyst Ratings
This is a breakdown of current ratings for Bluejay Diagnostics and ENDRA Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
ENDRA Life Sciences has a consensus price target of $50.00, indicating a potential upside of 715.66%. Given ENDRA Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Bluejay Diagnostics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Bluejay Diagnostics | N/A | -362.07% | -299.10% |
| ENDRA Life Sciences | N/A | -194.14% | -127.89% |
Volatility and Risk
Bluejay Diagnostics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500.
Institutional and Insider Ownership
18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 0.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Bluejay Diagnostics and ENDRA Life Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bluejay Diagnostics | $250,000.00 | 15.38 | -$7.72 million | ($125.15) | -0.02 |
| ENDRA Life Sciences | N/A | N/A | -$11.51 million | ($33.89) | -0.18 |
Bluejay Diagnostics has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
